Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigms AGM Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm in-licenses treatment for rare joint disease
- Paradigm receives $2.32m R&D tax incentive refund
- PAR reports pain reduction in 145 people with osteoarthritis
- Paradigm Agreement With USA Past Players Network
- Paradigms Updated Corporate Presentation
Later from Paradigm Biopharmaceuticals
- Paradigm reports consistent oa pain reduction
- PAR reports successful phase 2 clinical trial
- Presentation of phase 2 clinical trial results
- Paradigms supplementary phase 2B data
- Paradigms orphan phase 2/3 clinical program progresses
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals